The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP

Douros, Jonathan D.Flak, Jonathan N.Knerr, Patrick J.2025-03-252025-03-252025-02-03Douros JD, Flak JN, Knerr PJ. The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP. Front Endocrinol (Lausanne). 2025;16:1530985. Published 2025 Feb 3. doi:10.3389/fendo.2025.1530985https://hdl.handle.net/1805/46567en-USAttribution 4.0 InternationalGIP - glucose-dependent insulinotropic peptideGLP-1 - glucagon-like peptide-1IncretinObesityPharmacologyThe agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIPArticle